Clinical Trials
23 trialsNCT06492616 2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT07174336 2026-05-22
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07349069 2026-05-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT07492641 2026-05-22
KANDELA-302
BeOne Medicines
Phase 3 Recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT05512364 2026-05-15
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT07085767 2026-05-15
OPERA-02
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT05827081 2026-05-14
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT05774951 2026-05-08
CAMBRIA-1
AstraZeneca
Phase 3 Recruiting
NCT06507618 2026-05-08
POWER II
University of Virginia
Phase 3 Recruiting
NCT06790693 2026-05-04
INAVO123
Hoffmann-La Roche
Phase 3 Recruiting
NCT04852887 2026-04-23
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT06072781 2026-04-02
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
NCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07024173 2026-01-26
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT07019363 2026-01-21
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
Phase 3 Recruiting
NCT04111978 2025-09-29
MATAO
Swiss GO Trial Group
Phase 3 Recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT03011684 2025-05-08
TALES
University of California, San Francisco
Phase 3 Recruiting
NCT05601700 2025-01-27
LEPRE
Ente Ospedaliero Ospedali Galliera
Phase 3 Recruiting
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting
NCT05851014 2023-05-09
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Genor Biopharma Co., Ltd.
Phase 3 Recruiting